46LOW

MYX

M PHARMA FPO [MYX]
Mayne Pharma Group Limited, a specialty pharmaceutical company, focuses on the commercialization of women's health and dermatology pharmaceuticals in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. It operates through three segments: Women's Health, Dermatology, and International. The company provides oral drug delivery systems, as well as contract development and manufacturing services to third-party customers. It also distributes specialty pharmaceutical products in the dermatology, women's health, and infectious disease therapeutic areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.
Healthcare · ASX Small Cap
$2.3000 -0.9%

Updated 26 Mar 2026 · Scores refresh every scan

Score Breakdown

Technical65
Catalyst86
Sentiment50
Fundamental87
Momentum33
Risk Gate45
Get alerts when MYX's score changes
Free watchlist with daily scans for 2,200+ ASX stocks
Track MYX — Free

Active Signals

Bullish Signals

  • RSI drifting toward oversold territory — worth watching
  • MACD momentum is picking up steam
  • Volume surging at 2.4x normal while price falls — heavy selling pressure
  • Smart money may be accumulating — volume is flowing in even though price hasn't moved yet
  • Cash positive / operating cashflow positive
  • Low P/S ratio (0.5x)
  • EPS estimates revised upward (+10pts)
  • Near 52-week low (5% of range)
  • New substantial holder(s) (1)
  • Substantial holder(s) ceased (1)
  • CANSLIM I: Institutional ownership (36%)
  • Sentiment is mixed — no strong consensus either way
  • Beneish M-Score -2.03 (grey zone -2.22 to -1.78): possible earnings manipulation
  • RBA hiking (-3pts)

Risk Signals

  • Below the 200-day average — the long-term trend is still working against it
  • Deeply negative margins (-20%)
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • Long-term momentum is negative — down 49% over the past year
  • The bigger volume days are the down days — volume-weighted momentum is negative (-0.73%/day)
  • Overseas neutral (-2pts, S&P500 neutral, VIX 25)
  • Fading catalyst: strong catalyst but declining momentum
Ask Scout AI about MYX
"What's driving MYX's score?" "How does MYX compare to peers?" "Key risks for MYX?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

LOW Mayne Pharma ASX SMIDcaps conference presentation
LOW Mayne Pharma to present at ASX SMIDcaps Conference
LOW DistributeRx Launch Investor Presentation
HIGH Becoming a substantial holder
HIGH Ceasing to be a substantial holder

Recent ASX Announcements

2026-03-25 Mayne Pharma ASX SMIDcaps conference presentation
2026-03-24 Becoming a substantial holder
2026-03-23 Ceasing to be a substantial holder
2026-03-16 Mayne Pharma to present at ASX SMIDcaps Conference
2026-03-10 DistributeRx Launch Investor Presentation

Key Metrics

$187.7M
Market Cap
596K
Avg Volume
2.4x
Vol Ratio
$2.04 — $7.29
52-Week Range
2.1%
Short Interest
N/A
Cash Runway
-20.6%
ROE
-20.4%
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 90%
LLeader vs LaggardlaggardRS: -6
IInstitutional SponsorshippassInst: 36%
MMarket DirectionneutralNeutral

Sector: Healthcare

Ranked #60 of 117 · Sector avg: 46

View all Healthcare signals →
Related Tickers
ATX 59PNV 56IMM 55EYE 55AHC 55
Compare:MYX vs ATXMYX vs PNVMYX vs IMM
Scout Pro — Deeper Analysis for MYX
Try Pro free for 30 days
Share this analysis

Track MYX and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and conviction scoring for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required